Navigation Links
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
Date:3/20/2008

- First New Agent for CLL Patients Approved by the FDA since 2001 -

FRAZER, Pa., March 20 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA(R) (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease. The American Cancer Society estimates that more than 15,000 new cases of this rare disease will be diagnosed in the United States this year. The TREANDA application as a CLL treatment received priority review from the FDA and was approved within six months of the September 2007 submission. Cephalon anticipates that TREANDA will be available to physicians and patients as a CLL treatment in the United States in April 2008.

To view the Multimedia News Release, go to:

http://www.prnewswire.com/mnr/treanda/32349/.

"TREANDA is an important new treatment for patients with chronic lymphocytic leukemia, and this first-cycle approval by FDA represents a significant milestone in the growth of our oncology business," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "With a strong pipeline of near- and longer-term opportunities, Cephalon Oncology is poised to deliver therapies that target both hematologic cancers and solid tumors for patients in need of new options."

Dr. Bruce Cheson, Clinical Professor of Hematology/Oncology, Georgetown University School of Medicine, Washington D.C., stated, "Patients with chronic lymphocytic leukemia can often live normal lives for many years because of treatments that control the disease over the long-term. TREANDA is an effective new option that offers a delay in disease progression, an important goal for patients with chronic lymphocytic leukemia."

In a randomized, international, m
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
2. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
3. Cephalon General Counsel John E. Osborn to Resign Position
4. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
5. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
6. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
7. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
8. Cephalon Submits Supplemental New Drug Application for FENTORA
9. Cephalon Announces Strong Third Quarter Financial Results
10. Cephalon Quarterly Conference Call Invitation
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/12/2010)... (BMCC) science major Kimberly Thompson wins $5,000 in CUNY Nobel ... ... NY (Vocus) March 12, 2010 -- Borough of Manhattan ... first place in the economics category of the 2009 CUNY ... Prizewinner., , , , ,Thompson--the contest,s only awardee from a ...
(Date:3/11/2010)... today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with ... ... , , ... ... ...
(Date:3/11/2010)... , ... , , ... ... ... EDMONTON , March 11 /PRNewswire/ - Today at ACAMP,s latest seminar, Alberta,s conventional energy industry learned how nanotechnology, micro-systems and ...
(Date:3/11/2010)... The Netherlands and SEATTLE, Washington , March 11, 2010 ,/PRNewswire/ ... regenerative medicine, today announced the,conclusion of the first Phase II trial testing its ... safety and efficacy (time to hemostasis),profiles for Fibrocaps, and good performance of the ... ... ...
Breaking Biology Technology:BMCC Student—the Only Community College Winner—Lands Grand Prize in Nobel Science Challenge 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 4FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 5FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 6FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 7FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 8Alberta companies delivering new products to the Conventional Energy marketplace 2Alberta companies delivering new products to the Conventional Energy marketplace 3ProFibrix Reports Phase II Results of Hemostasis Product Fibrocaps(TM) and Appoints New Chief Medical Officer 2ProFibrix Reports Phase II Results of Hemostasis Product Fibrocaps(TM) and Appoints New Chief Medical Officer 3
... scale of September 11 or Hurricane Katrina, but technology ... ensure the Badger State responds more like New York ... Management Planning Project, conceived following September 11, was outlined ... WTN Media last week. Those in attendance included private-sector ...
... Can a Mac really be hacked in just 30 minutes? Not ... engineer, who criticized recent media reports for sensationalism after they reported ... a computer gave out login accounts to potential hackers. , ,In ... been given access to the computer to take full control of ...
... the inboxes of their subscribers, it's time to consider the ... , ,The right inbox? Priceless. , ,Unwanted e-mail, or spam, ... uncommon for inboxes to average hundreds of e-mails a day, ... or relevant. Most consumers have some degree of spam filtering ...
Other Biology Technology:State initiative prepares Wisconsin IT systems for a disaster 2State initiative prepares Wisconsin IT systems for a disaster 3What's an inbox worth? 2What's an inbox worth? 3What's an inbox worth? 4
(Date:3/12/2010)... COLLEGE STATION - - Using green algae to produce ... has been doing so for hundreds of millions of ... from the green algae Botryococcus braunii can ... suggesting that B. braunii has been a ... major contributor," said Dr. Timothy Devarenne, AgriLife Research scientist ...
(Date:3/12/2010)... 12, 2010 Keystone Symposia on Molecular and ... a $1.37 million, five-year MARC (Minority Access to ... National Institute of General Medical Sciences of the ... Ethnic Minority Scientists and Trainees at Keystone Symposia," ... enhance participation in biomedical research by historically underrepresented ...
(Date:3/12/2010)... release is available in Spanish . , ... for reducing bone fractures. But a study supported in ... importance of vitamin D and its ability to help ... why increasing calcium alone isn,t always successful in dealing ... not tied to vitamin D status, which may explain ...
Breaking Biology News(10 mins):AgriLife scientists do groundwork for genetic mapping of algae biofuel species 2AgriLife scientists do groundwork for genetic mapping of algae biofuel species 3Keystone Symposia awarded $1.37 million, 5-year NIH grant to fund ongoing diversity efforts 2Keystone Symposia awarded $1.37 million, 5-year NIH grant to fund ongoing diversity efforts 3Keystone Symposia awarded $1.37 million, 5-year NIH grant to fund ongoing diversity efforts 4Vitamin D and calcium interplay explored 2Scripps research team develops technique to determine ethnic origin of stem cell lines 11287 1Scripps research team develops technique to determine ethnic origin of stem cell lines 11287 2Scripps research team develops technique to determine ethnic origin of stem cell lines 11287 3Childrens Hospital Brings Hope to Special Babies and Their Families 64036 1Childrens Hospital Brings Hope to Special Babies and Their Families 64036 2Childrens Hospital Brings Hope to Special Babies and Their Families 64036 3Childrens Hospital Brings Hope to Special Babies and Their Families 64036 4Los Angeles Healthcare Fraud Defense Lawyers Announce Recent Results in California Medi Cal and Medi Care Criminal Law Cases 64033 1Los Angeles Healthcare Fraud Defense Lawyers Announce Recent Results in California Medi Cal and Medi Care Criminal Law Cases 64033 2Los Angeles Healthcare Fraud Defense Lawyers Announce Recent Results in California Medi Cal and Medi Care Criminal Law Cases 64033 3
... Shipwrecks on coral reefs may increase invasion of unwanted ... These unwanted species can completely overtake the reef and ... of marine organisms on the reef. This study documents ... the dominant biota on a coral reef is unambiguously ...
... An international team led by NYU Cancer Institute have ... which are found on virtually all mature human cells and ... new report, published this week by Developmental Cell ... edition, describes how three proteins work together to regulate the ...
... WI, August 18, 2008 -- Like most things that ... but while flowers, leaves, and other aboveground plant parts ... our appreciation. Beneath every towering tree, tasty crop, and ... all possible. Roots provide anchor and support for plants, ...
Other Biology News:Shipwrecks on coral reefs harbor unwanted species 2NYU scientists identify critical protein complex in formation of cell cilia 2Getting to the root of the matter 2
... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
MBS 384 well satellite block unit with height adjusting heated lid, 384 well block holds 1 x 0.04 ml 384 well plate...
... Overview: Once a macromolecular structure has been ... information to a widely diverse audience of ... the printed literature and dissemination over the ... on personal web pages. Printed literature has ...
... Angle rotor for use in ... CL3/CL3R, HN-SII or Centra MP4/MP4R. ... accepts 15 mL round bottom, ... tubes as well as popular ...
Biology Products: